UK & Europe

A London high court judge ruled this week that the damages paid to the NHS for an anticompetitive

Judge shuts down Servier’s argument that NHS should have stopped prescribing its drugs

https://pharmaphorum.com/news/judge-shuts-down-serviers-argument-that-nhs-should-have-stopped-prescribing-its-drugs/

Events/ Events/ Partner Content/ Sales and Marketing/ UK & Europe/ US

The Pharma Forecasting Workshop – Fundamentals of Forecasting, Zurich

Jenny Meakin biosimilars, forecasting, Oncology, pharma, Training

J+D Interactive Pharma Forecasting Workshop

The Pharma Forecasting Workshop – Fundamentals of Forecasting, Zurich

https://pharmaphorum.com/events/jd-pharma-forecasting-workshop-london/

Brexit/ Market Access/ UK & Europe/ Views & Analysis/ Views and analysis

UK’s drug supply contingency plan for hard Brexit

Piotr Wnuk Brexit, Brexit contingency plan, Brexit Health Alliance, Matt Hancock, no-deal Brexit 0 Comment

The UK government has issued several documents to help businesses in planning for the eventuality of a no-deal

UK’s drug supply contingency plan for hard Brexit

https://pharmaphorum.com/views-analysis-market-access/hard-brexit-uk-drug-supply-contingency-plan/

News/ UK & Europe

Ipsen appoints new general manager for the UK & Ireland

Piotr Wnuk appointments, Ipsen 0 Comment

The French pharma company appointed a new general manager for its UK and Ireland office, Asad Mohsin Ali,

Ipsen appoints new general manager for the UK & Ireland

https://pharmaphorum.com/news/ipsen-appoints-new-general-manager/

Market Access/ News/ News/ News/ R&D/ UK & Europe

Sanofi’s rare disease drug Cablivi approved in the EU

Piotr Wnuk acquired thrombotic thrombocytopenic purpura, aTTP, Cablivi, haemophilia, haemotology, Sanofi 0 Comment

The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired

Sanofi’s rare disease drug Cablivi approved in the EU

https://pharmaphorum.com/news/sanofi-cablivi-approved-europe/

AstraZeneca/ Diabetes/ Diabetes/ News/ News/ R&D/ UK & Europe

AstraZeneca improves diabetes pen to maintain its market share

Piotr Wnuk AstraZeneca, Bydureon, Diabetes, GLP-1 0 Comment

The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug

AstraZeneca improves diabetes pen to maintain its market share

https://pharmaphorum.com/news/astrazeneca-improves-diabetes-pen-to-maintain-its-market-share/

News/ News/ Patients/ UK & Europe

England reveals plans allowing abortion pill to be taken at home

Piotr Wnuk abortion, gynaecology, mifepristone, misoprostol 0 Comment

Women in England will be able to take an early abortion pill in the safety of their own

England reveals plans allowing abortion pill to be taken at home

https://pharmaphorum.com/news/england-reveals-plans-allowing-abortion-pill-to-be-taken-at-home/

AstraZeneca/ News/ UK & Europe

AstraZeneca changes contractors as HQ delayed again

Piotr Wnuk AstraZeneca, Cambridge (UK) 0 Comment

AstraZeneca has switched building contractors in a bid to hasten progress on its delayed and over-budget new headquarters,

AstraZeneca changes contractors as HQ delayed again

https://pharmaphorum.com/news/astrazeneca-changes-contractors-as-hq-delayed-again/

Market Access/ UK & Europe/ Views & Analysis/ Views and analysis

Brexit from the inside: MP’s views on how it will impact pharma

Piotr Wnuk Brexit, pharmaceutical trade, politics 0 Comment

With the potential for a hard-no-deal Brexit becoming closer to reality with each passing day, the question of

Brexit from the inside: MP’s views on how it will impact pharma

https://pharmaphorum.com/views-and-analysis/brexit-inside-mps-views-impact-pharma/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

UK & Europe

Login